Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesdsay , March 19 th , 2019 starting at 9:30
View HTML
Toggle Summary Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone-receptor-positive breast cancer SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
View HTML
Toggle Summary Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®
SAN DIEGO , March 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851 , part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference
SAN DIEGO , March 05, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the Cowen 39th Annual Healthcare Conference on Tuesday, March 12, 2019 at 8:40
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference
SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference
SAN DIEGO , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019 at 9:45 a.m.
View HTML
Toggle Summary Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
Bacterial vaginosis affects nearly 20 million women in the U.S. every year SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling
View HTML